Buy Pharmacom Labs Hennos 10 Oral Steroid 50 tabs

Description

Buy Pharmacom Labs Hennos 10 Oral Steroid 50 tabs

Product Description: Hennos Oral 10mg Tablets (GW1516 / Cardarine)

Hennos Oral 10mg Tablets are presented in a convenient blister pack containing 50 tablets, each formulated with 10mg of GW1516 (also known as Cardarine or GW501516). GW1516 is a synthetic peroxisome proliferator-activated receptor delta (PPARδ) agonist that was originally investigated for its potential applications in metabolic disorders, dyslipidemia, insulin resistance, and cardiovascular diseases. By activating PPARδ, the compound influences fatty acid oxidation and energy metabolism.

Each tablet provides a precise 10mg dose, and the blister packaging ensures product integrity, stability, and convenient storage. This product is intended for research purposes or as directed by a healthcare professional.

Important Safety Information

GW1516 was withdrawn from clinical trials after preclinical studies demonstrated a significant increase in cancer development in animal models. Regulatory authorities including the U.S. Food and Drug Administration (FDA) have issued warnings regarding products containing this substance. The World Anti-Doping Agency (WADA) has prohibited GW1516 since 2009 due to its potential to artificially enhance endurance. The Therapeutic Goods Administration (TGA) lists GW1516 under Schedule 10 – substances of such danger to health as to warrant prohibition of sale, supply and use.

This compound has not been approved for human therapeutic use, and no long-term human safety data exists. Potential adverse effects documented in clinical and preclinical research include carcinogenicity, reproductive toxicity, reduced bone mineral density, and compromised bone integrity.

Always consult with a qualified healthcare provider before using any research compound. The information provided herein is for educational and informational purposes only.

---

Top 10 FAQs About Hennos Oral 10mg Tablets (GW1516 / Cardarine)

1. What is GW1516 (Cardarine)?
GW1516, also known as Cardarine or GW501516, is a synthetic PPARδ receptor agonist. It was developed as a potential treatment for metabolic and cardiovascular conditions but was never approved for human use.

2. How does GW1516 work in the body?
GW1516 activates PPARδ receptors, which regulate fatty acid oxidation and energy metabolism. This mechanism influences how the body utilises fats for energy.

3. What is the typical dosage range for GW1516?
In research contexts, oral dosages of 10 to 20 mg per day for cycles of 6 to 8 weeks have been documented. A starting dose of 10mg daily is commonly used to assess tolerance. Always follow the guidance of a qualified professional.

4. Is GW1516 approved for human use?
No. GW1516 has not been approved by any regulatory authority for human therapeutic use. Clinical trials were discontinued after animal studies demonstrated a significant increase in cancer development.

5. What are the known risks and side effects?
Preclinical studies have associated GW1516 with carcinogenicity, reproductive toxicity, reduced bone mineral density, and compromised bone integrity. The long-term effects in humans have not been established.

6. Is GW1516 legal to buy and use?
GW1516 is prohibited by the World Anti-Doping Agency (WADA). It is listed as a Schedule 10 substance in Australia, indicating prohibition of sale, supply, and use. The FDA has issued warnings regarding products containing this substance.

7. Why was GW1516 discontinued from clinical trials?
Clinical development was halted because animal studies revealed a significant increase in cancer development, including a fivefold increase in intestinal polyps larger than 2mm in mouse models.

8. Can GW1516 enhance athletic performance?
GW1516 has been shown in animal studies to improve running endurance and increase oxidative muscle fibres. However, it is prohibited by WADA and carries significant health risks.

9. Are there any human studies on GW1516?
No comprehensive long-term human studies have been conducted. The compound was withdrawn from development before progressing to extensive human trials due to safety concerns identified in preclinical research.

10. Where can I find more information about GW1516?
Authoritative sources include the U.S. Anti-Doping Agency (USADA) at usada.org, the Therapeutic Goods Administration (TGA) at tga.gov.au, and the FDA at fda.gov. Peer-reviewed literature is available via PubMed (pubmed.ncbi.nlm.nih.gov).

---

References

• U.S. Anti-Doping Agency (USADA): What Should Tested Athletes Know About GW1516? [usada.org]

• Therapeutic Goods Administration (TGA): Cardarine (GW501516) information [tga.gov.au]

• WebMD: Cardarine – Overview, Uses, Side Effects [webmd.com]

• Healthline: Cardarine – Benefits, Side Effects, Dosage [healthline.com]

• PubMed: Novel Solid Forms of Cardarine/GW501516 [pubmed.ncbi.nlm.nih.gov]

• PubMed: Synthesis and analysis of GW1516 [pubmed.ncbi.nlm.nih.gov]

• FDA Warning Letters regarding Cardarine products [fda.gov]

---

For more information or to place an order, please visit: https://anabolicsteroidsonline.shop/